Galera Therapeutics Analyst Ratings
Galera Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest Galera Therapeutics (GRTX) rating was a maintained with a price target of $0.40 to $0.25. The current price Galera Therapeutics (GRTX) is trading at is $0.20, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/29/2023 | 23.58% | Citigroup | $0.4 → $0.25 | Maintains | Neutral |
| 08/16/2023 | 48.29% | HC Wainwright & Co. | $6 → $0.3 | Downgrades | Buy → Neutral |
| 08/10/2023 | 147.16% | Piper Sandler | $6 → $0.5 | Downgrades | Overweight → Neutral |
| 07/17/2023 | 2865.89% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 03/22/2023 | 2865.89% | HC Wainwright & Co. | $10 → $6 | Maintains | Buy |
| 02/21/2023 | 2865.89% | Piper Sandler | → $6 | Initiates Coverage On | → Overweight |
| 02/16/2023 | 3360.21% | B of A Securities | $2 → $7 | Upgrades | Underperform → Buy |
| 02/16/2023 | 4843.15% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 05/27/2022 | 888.63% | B of A Securities | → $2 | Downgrades | Neutral → Underperform |
| 12/20/2021 | 9786.31% | Citigroup | $11 → $20 | Maintains | Buy |
| 12/15/2021 | 4843.15% | HC Wainwright & Co. | → $10 | Upgrades | Neutral → Buy |
| 12/15/2021 | 7314.73% | BTIG | → $15 | Upgrades | Neutral → Buy |
| 10/20/2021 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 10/19/2021 | — | BTIG | Downgrades | Buy → Neutral | |
| 12/16/2020 | 7314.73% | Credit Suisse | $9 → $15 | Upgrades | Neutral → Outperform |
| 12/07/2020 | 7314.73% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
| 11/11/2020 | 4348.84% | Credit Suisse | $8 → $9 | Maintains | Neutral |
| 07/29/2020 | 3854.52% | Credit Suisse | $14 → $8 | Maintains | Neutral |
| 12/02/2019 | 14729.46% | BTIG | → $30 | Initiates Coverage On | → Buy |
| 12/02/2019 | 7314.73% | B of A Securities | → $15 | Initiates Coverage On | → Buy |
| 12/02/2019 | 9786.31% | Citigroup | → $20 | Initiates Coverage On | → Buy |
| 12/02/2019 | 6820.42% | Credit Suisse | → $14 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月29日 | 23.58% | 花旗集團 | $0.4→$0.25 | 維護 | 中性 |
| 08/16/2023 | 48.29% | HC Wainwright公司 | $6→$0.3 | 評級下調 | 購買→中性 |
| 2023年08月10日 | 147.16% | 派珀·桑德勒 | $6→$0.5 | 評級下調 | 超重→中性 |
| 07/17/2023 | 2865.89% | HC Wainwright公司 | →$6 | 重申 | 購買→購買 |
| 03/22/2023 | 2865.89% | HC Wainwright公司 | $10→$6 | 維護 | 買 |
| 02/21/2023 | 2865.89% | 派珀·桑德勒 | →$6 | 開始承保 | →超重 |
| 02/16/2023 | 3360.21% | B of A證券 | $2→$7 | 升級 | 表現不佳的→收購 |
| 02/16/2023 | 4843.15% | HC Wainwright公司 | →$10 | 重申 | →購買 |
| 2022年05月27日 | 888.63% | B of A證券 | →$2 | 評級下調 | 中性→表現不佳 |
| 12/20/2021 | 9786.31% | 花旗集團 | $11→$20 | 維護 | 買 |
| 2021年12月15日 | 4843.15% | HC Wainwright公司 | →$10 | 升級 | 中性→購買 |
| 2021年12月15日 | 7314.73% | BTIG | →$15 | 升級 | 中性→購買 |
| 10/20/2021 | - | HC Wainwright公司 | 評級下調 | 購買→中性 | |
| 10/19/2021 | - | BTIG | 評級下調 | 購買→中性 | |
| 12/16/2020 | 7314.73% | 瑞士信貸 | $9→$15 | 升級 | 中性→表現優異 |
| 12/07/2020 | 7314.73% | HC Wainwright公司 | →$15 | 開始承保 | →購買 |
| 11/11/2020 | 4348.84% | 瑞士信貸 | $8→$9 | 維護 | 中性 |
| 07/29/2020 | 3854.52% | 瑞士信貸 | $14→$8 | 維護 | 中性 |
| 2019年2月12日 | 14729.46% | BTIG | →$30 | 開始承保 | →購買 |
| 2019年2月12日 | 7314.73% | B of A證券 | →$15 | 開始承保 | →購買 |
| 2019年2月12日 | 9786.31% | 花旗集團 | →$20 | 開始承保 | →購買 |
| 2019年2月12日 | 6820.42% | 瑞士信貸 | →$14 | 開始承保 | →中性 |
What is the target price for Galera Therapeutics (GRTX)?
Galera治療公司(GRTX)的目標價格是多少？
The latest price target for Galera Therapeutics (NASDAQ: GRTX) was reported by Citigroup on August 29, 2023. The analyst firm set a price target for $0.25 expecting GRTX to rise to within 12 months (a possible 23.58% upside). 8 analyst firms have reported ratings in the last year.
花旗集團於2023年8月29日報道了Galera治療公司(納斯達克：GRTX)的最新目標價。這家分析公司將目標價定為0.25美元，預計GRTX將在12個月內升至(可能上漲23.58%)。去年有8家分析公司公佈了評級。
What is the most recent analyst rating for Galera Therapeutics (GRTX)?
Galera治療公司(GRTX)的最新分析師評級是多少？
The latest analyst rating for Galera Therapeutics (NASDAQ: GRTX) was provided by Citigroup, and Galera Therapeutics maintained their neutral rating.
花旗集團提供了對加萊拉治療公司(納斯達克代碼：GRTX)的最新分析師評級，加萊拉治療公司維持其中性評級。
When is the next analyst rating going to be posted or updated for Galera Therapeutics (GRTX)?
Galera治療公司(GRTX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galera Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galera Therapeutics was filed on August 29, 2023 so you should expect the next rating to be made available sometime around August 29, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Galera治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Galera治療公司的上一次評級是在2023年8月29日提交的，因此您應該預計下一次評級將在2024年8月29日左右提供。
Is the Analyst Rating Galera Therapeutics (GRTX) correct?
分析師對Galera Treateutics(GRTX)的評級正確嗎？
While ratings are subjective and will change, the latest Galera Therapeutics (GRTX) rating was a maintained with a price target of $0.40 to $0.25. The current price Galera Therapeutics (GRTX) is trading at is $0.20, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Galera治療公司(GRTX)評級保持不變，目標價在0.40美元至0.25美元之間。Galera治療公司(GRTX)目前的交易價格為0.20美元，超出了分析師的預測範圍。